---
---

```{r include = F}
#| setup
if (!requireNamespace("utils.tool"))
  devtools::load_all("~/utils.tool/")
autor_preset()
## the package are available at <https://github.com/shaman-yellow/utils.tool>
## if you want to run codes of this Rmarkdown,
## please install the package `utils.tool` and other related packages (run
## install.R)
options(savedir = list(figs = "Figure+Table", tabs = "Figure+Table"))
```

```{r eval = T, echo = F, results = "asis"}
set_index()
```

# 摘要 {#abstract}

筛选丹参酮治疗脓毒症（sepsis）的关键差异表达基因及相关信号通路。

# 材料和方法 {#methods}

测序数据：Caco-2细胞系，对照组con，脂多糖组LPS，丹参酮组TNA（LPS+TNA）。

GEO 数据：GSE237861

# 研究设计流程图 {#route}

```{r}
#| route
route <- as_network(
  list("data:RNA_data, GSE...",
    "RNA_data:DEGs",
    "DEGs:modify_up, modify_down",
    "modify_up, modify_down:enrichment",
    "enrichment:pathway",
    "pathway:matched_genes",
    "GSE...,:tissues",
    "matched_genes:tissues",
    "tissues:intersection",
    "intersection:Docking",
    "Docking:critical_genes"
  ), "tree"
)
p.route <- flowChart(route, 1.1, 1)
```

```{r, eval = T, echo = F, fig.width = 7, fig.height = 7, fig.cap = NULL}
p.route
```

# 分析结果 {#results}

单以测序数据集筛选到 1797 个靶点，富集分析聚焦到 Hippo 通路（Fig. \@ref(fig:genes-enriched-in-hippo-signiling-pathway)）。

以 GEO 数据 GSE237861 分析发现，6 种不同组织的 sepsis 病例存在 51 个共同的差异表达基因（Disease vs control）。进一步分析发现：无同时存在于 6 或 5 种组织的Hippo 通路基因（同时也是 Tanshinone IIA 的作用靶点）；_BIRC3_、_ID1_ 在 4 种组织中差异表达；_DLG4_ 在 3 种组织中差异表达（Fig. \@ref(fig:Target-genes-of-TNA-in-mutiple-tissue-of-sepsis-of-Hippo-pathway)）。分子对接显示，SMAD7, SOX2, TGFBR2, DLG4, DLG2 具有良好亲和度（Fig. \@ref(fig:docking-affinity)）。综上，*DLG4* 在 3 种sepsis 组织中差异表达，且 DLG4 可与 Tanshinone IIA 结合，因此，*DLG4* 可能是 TNA 治疗 sepsis 的关键靶点之一，对应信号通路为 Hippo。

# 结论 {#dis}

*DLG4* 可能是 TNA 治疗 sepsis 的关键靶点，相关信号通路为 Hippo。

# 附：分析流程

## 测序数据

### 差异分析

```{r}
counts <- ftibble("./raw/gene_count.csv")

metadata <- group_strings(colnames(counts)[-1],
  c(control = "^con", model = "^LPS", treatment = "^TNA"), "sample")

mart <- new_biomart()
anno <- filter_biomart(mart, general_attrs(), "ensembl_gene_id", counts$gene_id)

lm <- job_limma(new_dge(metadata, counts, anno))
lm <- step1(lm)
lm <- step2(lm, treatment - model, model - control)
lm <- step3(lm, c("treatment_vs_model", "model_vs_control"))
lm@plots$step3$p.sets_intersection

treat_all_sets <- list(
  up = ins(lm@params$sets_intersection$treatment_vs_model.up, lm@params$sets_intersection$model_vs_control.down),
  down = ins(lm@params$sets_intersection$treatment_vs_model.down, lm@params$sets_intersection$model_vs_control.up)
)
treat_all <- unique(unlist(treat_all_sets))
```

```{r eval = T, echo = F, results = "asis"}
#| Low-expression-filtering
autor(lm@plots$step1$p.filter)
```

```{r eval = T, echo = F, results = "asis"}
#| expression-normalization
autor(lm@plots$step1$p.norm)
```

```{r eval = T, echo = F, results = "asis"}
#| DEGs-of-model-versus-control
autor(lm@plots$step2$p.valcano[[2]])
```

```{r eval = T, echo = F, results = "asis"}
#| table-of-DEGs-of-model-versus-control
autor(lm@tables$step2$tops[[2]])
```

```{r eval = T, echo = F, results = "asis"}
#| DEGs-of-treatment-versus-model
autor(lm@plots$step2$p.valcano[[1]])
```

```{r eval = T, echo = F, results = "asis"}
#| table-of-DEGs-of-treatment-versus-model
autor(lm@tables$step2$tops[[1]])
```

丹参酮的疗效有两种情况：

- 模型组相比对照组，基因上调；而以丹参酮处理后，基因下调（相比于模型组）。
- 模型组相比对照组，基因下调；而以丹参酮处理后，基因上调（相比于模型组）。

```{r eval = T, echo = F, results = "asis"}
#| intersection-of-disease-genes-expression-and-treatment-effect-of-TNA
autor(lm@plots$step3$p.sets_intersection)
```

取 Fig. \@ref(fig:intersection-of-disease-genes-expression-and-treatment-effect-of-TNA) 的两组交集的合集（989 + 808），。

### 富集分析

```{r}
en0 <- job_enrich(list(ids = treat_all), anno)
en0 <- step1(en0)

en0@plots$step1$p.kegg$ids
en0@plots$step1$p.go$ids
en0@tables$step1$res.kegg$ids

en0 <- step2(en0, "hsa04390")
en0@plots$step2$p.pathviews$hsa04390

treat_hippo <- en0@tables$step1$res.kegg$ids[2, ]$geneName_list[[1]]
```

以上述合集做富集分析。

```{r eval = T, echo = F, results = "asis"}
#| KEGG-enrichment
autor(en0@plots$step1$p.kegg$ids)
```

Hippo 通路为显著富集通路。

```{r eval = T, echo = F, results = "asis"}
#| genes-enriched-in-hippo-signiling-pathway
autor(en0@plots$step2$p.pathviews$hsa04390)
```

## GEO sepsis

### GSE237861: Transcriptome analysis of six tissues obtained post mortem from sepsis patients

```{r}
geo <- job_geo("GSE237861")
geo <- step1(geo)
geo <- step2(geo)

geo@params$prods
geo@params$guess

lapply(list.files("./GSE237861/", "\\.gz$", full.names = T), R.utils::gunzip)
geo.res <- sapply(list.files("./GSE237861/", "\\.tsv$", full.names = T), ftibble, simplify = F)

geo.summary <- lapply(geo.res,
  function(data) {
    symbols <- filter(data, FDR < .05, abs(logFC) > .3)$gene_ID
    gs(symbols, "\\.[0-9]*$", "")
  })
fun <- function(x) {
  tissue <- unique(gs(names(x), ".*\\.([a-z]*).tsv", "\\1"))
  meta <- group_strings(names(x), nl(tissue, tissue, as.list = F))
  meta <- mutate(meta, sample = stringr::str_extract(target, "sepsis[0-9]"),
    diff_number = vapply(target, function(x) length(geo.summary[[ x ]]), integer(1))
  )
  ## heatmap
  data <- select(meta, -target, tissue = group, patient = sample)
  obj <- new_heatdata(.data_long(data))
  obj@aesn$lab_fill <- "Number"
  p.hp <- wrap(callheatmap(obj), 5, 4)
  ## upset
  lst <- split(meta$target, meta$group)
  lst <- lapply(lst,
    function(x){
      unique(unlist(geo.summary[ names(geo.summary) %in% x ]))
    })
  p.upset <- wrap(new_upset(lst = lst), 12, 6)
  upset.ins <- ins(lst = lst)
  upset.set <- lst
  namel(p.hp, p.upset, upset.ins, upset.set)
}
geo.plots <- fun(geo.summary)
geo.plots$upset.ins

geo.plots$p.hp
```

```{r eval = T, echo = F, results = "asis"}
#| prods
autor(geo@params$prods)
```

```{r eval = T, echo = F, results = "asis"}
#| metadata-of-GSE237861
autor(geo@params$guess)
```

```{r eval = T, echo = F, results = "asis"}
#| DEGs-number-in-sepsis-of-mutiple-tissue-of-GEO-dataset
autor(geo.plots$p.hp)
```

在六种不同的 sepsis 组织中，共有 51 个共同的交集基因（Fig. \@ref(fig:intersection-of-DEGs-of-mutiple-tissue-of-sepsis)）。

```{r eval = T, echo = F, results = "asis"}
#| intersection-of-DEGs-of-mutiple-tissue-of-sepsis
autor(geo.plots$p.upset)
```

## 整合：测序数据和 GEO 数据

### 关联基因

```{r}
#| strict
coTarget <- intersect(geo.plots$p.upset.ins, treat_all)
```

```{r}
#| loose
matched.lst <- lapply(geo.plots$upset.set, function(x) intersect(x, treat_hippo))
data_net <- as_df.lst(matched.lst, "tissue", "genes")
p.allu <- new_allu(data_net)
```

以 GSE237861 验证 TNA 作用的 Hippo 通路基因，属于 sepsis 哪些组织的差异表达基因，以确认 TNA 是否对其具有疗效。

- BIRC3、ID1 在 4 种组织中差异表达
- DLG4 在 3 种组织中差异表达
- ...

```{r eval = T, echo = F, results = "asis"}
#| Target-genes-of-TNA-in-mutiple-tissue-of-sepsis-of-Hippo-pathway
autor(p.allu)
```

### 分子对接

丹参酮 I（Tanshinone IIA, CID:164676）

以 AutoDock Vina 对 Fig. \@ref(fig:Target-genes-of-TNA-in-mutiple-tissue-of-sepsis-of-Hippo-pathway) 所示基因的蛋白以 Tanshinone IIA分子对接。

结果显示，SMAD7, SOX2, TGFBR2, DLG4, DLG2 具有良好亲和度。

结合 Fig. \@ref(fig:Target-genes-of-TNA-in-mutiple-tissue-of-sepsis-of-Hippo-pathway) 所示的多组织差异表达，DLG4 同时在 3 种组织 sepsis 差异表达，且为 TNA 作用靶点，表现良好对接亲和度，可能是 TNA 治疗的关键靶点之一。

```{r}
vn <- job_vina("164676", unique(unlist(matched.lst, use.names = F)))
vn <- step1(vn, NULL)
vn <- step2(vn)
vn <- step3(vn)
vn <- step4(vn)
vn <- step5(vn, data.frame(cid = 164676, name = "Tanshinone IIA"), "cid", "name")
paste(vn@tables$step5$unique_tops$hgnc_symbol, collapse = ", ")

vn <- step6(vn)
options(step_check = F)
vn <- step7(vn)
```

```{r eval = T, echo = F, results = "asis"}
#| docking-affinity
autor(wrap(vn@plots$step5$p.res_vina, 6, 4))
```

```{r eval = T, echo = F, results = "asis"}
#| Tanshinone-IIA-binding-with-protein-DLG4
autor(.file_fig("./figs/164676_into_1kef.png"))
```

# 附：补充分析流程

补充分析：进一步筛选与肠道微生物和免疫微环境相关的差异表达基因

- Distinct subsets of neutrophils crosstalk with cytokines and metabolites in patients with sepsis
  PMID: 36756375

```{r}
# colon.DEGs <- geo.plots$upset.set$colon
gdb <- ftibble("../Gut Microbe and Metabolite-human.txt")
```

- Integrative analysis of metabolomics and proteomics reveals amino acid metabolism disorder in sepsis
    - PMID: 35287674
    - Blood samples were collected from patients diagnosed with sepsis at
      admission to the ICU. Blood samples of patients and NC subjects were
      drawn using serum separation tubes and allowed to clot at room
      temperature for 60 min. The samples were centrifuged for 10 min within 30
      min (1600×g, 4 °C) to remove insoluble solids. Each aliquot of serum was
      collected and immediately stored at − 80 °C until ultrahigh-performance
      liquid chromatography with quadrupole time-of-flight mass spectrometry
      (UPLC-Q-TOF/MS) analysis.


